metocor 50 mg/1 tableta tableta
zada pharmaceuticals d.o.o. - метопролол - tableta - 50 mg/1 tableta - 1 tableta sadrži: 50 mg metoprolol tartarata
metocor 100 mg/1 tableta tableta
zada pharmaceuticals d.o.o. - метопролол - tableta - 100 mg/1 tableta - 1 tableta sadrži: 100 mg metoprolol tartarata
aricept evess 5 mg/1 tableta oralna disperzibilna tableta
pfizer bh d.o.o. - donepezil - oralna disperzibilna tableta - 5 mg/1 tableta - 1 oralna disperzibilna tableta sadrži: 5 mg donepezilhlorida
aricept evess 10 mg/1 tableta oralna disperzibilna tableta
pfizer bh d.o.o. - donepezil - oralna disperzibilna tableta - 10 mg/1 tableta - 1 oralna disperzibilna tableta sadrži: 10 mg donepezilhlorida
barios 5 mg/1 tableta tableta
hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - Небиволол - tableta - 5 mg/1 tableta - 1 tableta sadrži: 5 mg nebivolola
corvitol 100 100 mg/1 tableta tableta
berlin chemie / menarini bh d.o.o. sarajevo - метопролол - tableta - 100 mg/1 tableta - 1 tableta sadrži:100 mg metoprolol tartarata
corvitol 50 50 mg/1 tableta tableta
berlin chemie / menarini bh d.o.o. sarajevo - метопролол - tableta - 50 mg/1 tableta - 1 tableta sadrži: 50 mg metoprololtartarata
ryeqo
gedeon richter plc. - relugolix, norethisterone acetate, estradiol hemihydrate - uterusa - hipofiza i hipotalamusni hormoni i analozi - ryeqo is indicated in adult women of reproductive age for:- treatment of moderate to severe symptoms of uterine fibroids,- symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.
drovelis
gedeon richter plc. - drospirenone, estetrol monohydrate - contraceptives, oral - spolni hormoni i modulatori genitalnog sustava, - oral contraceptive.
lydisilka
estetra sprl - estetrol monohydrate, drospirenone - contraceptives, oral - spolni hormoni i modulatori genitalnog sustava, - oralna kontracepcija. the decision to prescribe lydisilka should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (vte), and how the risk of vte with lydisilka compares with other combined hormonal contraceptives (chcs) (see sections 4. 3 and 4.